Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees

American Journal of Psychiatry

Volumn 166, Issue 11, 2009, Pages 1269-1277

  Brodie, Jonathan D ^a   Case, Brady G ^a   Figueroa, Emilia ^a   Dewey, Stephen L ^a   Robinson, James A ^a   Wanderling, Joseph A ^a   Laska, Eugene M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; COCAINE; PLACEBO; VIGABATRIN;

ABDOMINAL DISEASE; ABSTINENCE; ADULT; ALCOHOL CONSUMPTION; ANXIETY; ARTICLE; CLINICAL ASSESSMENT; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COCAINE DEPENDENCE; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EYE DISCOMFORT; FEMALE; GASTRITIS; HELP SEEKING BEHAVIOR; HUMAN; HYPERTENSION; INSOMNIA; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MEXICO; NOSE DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SOMNOLENCE; THROAT DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; URINALYSIS; VISUAL IMPAIRMENT; WITHDRAWAL SYNDROME;

ADULT; ALCOHOLISM; ANTICONVULSANTS; COCAINE-RELATED DISORDERS; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEXICAN AMERICANS; PLACEBOS; SEVERITY OF ILLNESS INDEX; SUBSTANCE ABUSE DETECTION; TEMPERANCE; TREATMENT OUTCOME; URBAN POPULATION; VIGABATRIN;

EID: 70449411191     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2009.08121811     Document Type: Article

References (39)

1. NIDA: Cocaine: Abuse and Addiction. Washington, DC, HHS, 2004
2. Leiderman DB, Shoptaw S, Montgomery A, Bloch DA, Elkashef A, LoCastro J, Vocci F: Cocaine Rapid Efficacy Screening Trial (CREST): a paradigm for the controlled evaluation of candidate medications for cocaine dependence. Addiction 2005; 100(suppl 1):1-11 (Pubitemid 40363420)
3. Carroll KM, Fenton LR, Ball SA, Nich C, Frankforter TL, Shi J, Rounsaville BJ: Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch Gen Psychiatry 2004; 61:264-272 (Pubitemid 38295828)
4. Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP: A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005; 30:205-211 (Pubitemid 40024415)
5. Kampman KM, Pettinati H, Lynch KG, Dackis C, Sparkman T, Weigley C, O'Brien CP: A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 2004; 75:233-240 (Pubitemid 38993293)
6. Kampman KM: The search for medications to treat stimulant dependence. Addict Sci Clin Pract 2008; 4:28-35
7. Gardner EL: Brain Reward Mechanisms in Substance Abuse: A Comprehensive Textbook. Baltimore, Williams and Wilkins, 1997
8. Dewey SL, Morgan AE, Ashby CR Jr, Horan B, Kushner SA, Logan J, Volkow ND, Fowler JS, Gardner EL, Brodie JD: A novel strategy for the treatment of cocaine addiction. Synapse 1998; 30:119-129 (Pubitemid 28376370)
9. Gerasimov MR, Schiffer WK, Gardner EL, Marsteller DA, Lennon IC, Taylor SJ, Brodie JD, Ashby CR Jr, Dewey SL: GABAergic blockade of cocaine-associated cue-induced increases in nucleus accumbens dopamine. Eur J Pharmacol 2001; 414:205-209
10. Volkow ND, Wang GJ, Fischman MW, Foltin RW, Fowler JS, Abumrad NN, Vitkun S, Logan J, Gatley SJ, Pappas N, Hitzemann R, Shea CE: Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 1997; 386:827-830 (Pubitemid 27181255)
11. 11C]-raclopride and positron emission tomography. J Neurosci 1992; 12:3773-3780
12. Molina PE, Ahmed N, Ajmal M, Dewey S, Volkow N, Fowler J, Abumrad N: Co-administration of gamma-vinyl GABA and cocaine: preclinical assessment of safety. Life Sci 1999; 65:1175-1182 (Pubitemid 29416748)
13. Petroff OA, Rothman DL, Behar KL, Collins TL, Mattson RH: Human brain GABA levels rise rapidly after initiation of vigabatrin therapy. Neurology 1996; 47:1567-1571
14. Mattson RH, Petroff OA, Rothman D, Behar K: Vigabatrin: effect on brain GABA levels measured by nuclear magnetic resonance spectroscopy. Acta Neurol Scand Suppl 1995; 162:27-30
15. Schiffer WK, Marsteller D, Dewey SL: Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine. Psychopharmacology (Berl) 2003; 168:339-343 (Pubitemid 36920918)
16. Kushner SA, Dewey SL, Kornetsky C: Gamma-vinyl GABA attenuates cocaine-induced lowering of brain stimulation reward thresholds. Psychopharmacology (Berl) 1997; 133:383-388
17. Kushner SA, Dewey SL, Kornetsky C: The irreversible gamma-aminobutyric acid (GABA) transaminase inhibitor gamma-vinyl-GABA blocks cocaine self-administration in rats. J Pharmacol Exp Ther 1999; 290:797-802
18. Stromberg MF, Mackler SA, Volpicelli JR, O'Brien CP, Dewey SL: The effect of gamma-vinyl-GABA on the consumption of concurrently available oral cocaine and ethanol in the rat. Pharmacol Biochem Behav 2001; 68:291-299
19. Takada K, Yanagita T: Drug dependence study on vigabatrin in rhesus monkeys and rats. Arzneimittelforschung 1997; 47:1087-1092 (Pubitemid 27451889)
20. Brodie JD, Figueroa E, Dewey SL: Treating cocaine addiction: from preclinical to clinical trial experience with gamma-vinyl GABA. Synapse 2003; 50:261-265 (Pubitemid 37315356)
21. Brodie JD, Figueroa E, Laska EM, Dewey SL: Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse 2005; 55:122-125 (Pubitemid 39665670)
22. Guy W: Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, HHS, 1976
23. Bruss GS, Gruenberg AM, Goldstein RD, Barber JP: Hamilton Anxiety Rating Scale Interview Guide: joint interview and test-retest methods for interrater reliability. Psychiatry Res 1994; 53:191-202
24. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6:278-296
25. Muñoz M, Cepeda-Benito A, Vila J, Fernandez MC: Development of two cocaine craving questionnaires, in Proceedings of the First International Research Collaboration Pre-conference to the Fourth National Conference: A Roadmap for Hispanic Drug Abuse Research. San Antonio, Tex, National Hispanic Science Network on Drug Abuse, 2004
26. McLellan AT, Lewis DC, O'Brien CP, Kleber HD: Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000; 284:1689-1695
27. Kosten TR, Gawin FH, Kosten TA, Morgan C, Rounsaville BJ, Schottenfeld R, Kleber HD: Six-month follow-up of short-term pharmacotherapy for cocaine dependence. Am J Addict 1992; 1:40-49
28. Berkson J, Gage RP: Survival curves for cancer patients following treatment. J Am Stat Assoc 1952; 47:501-515
29. Laska EM, Meisner MJ: Nonparametric estimation and testing in a cure model. Biometrics 1992; 48:1223-1234
30. Carroll KM, Rounsaville BJ, Nich C, Gordon L, Gawin F: Integrating psychotherapy and pharmacotherapy for cocaine dependence: results from a randomized clinical trial. NIDA Res Monogr 1995; 150:19-35
31. Carroll KM, Rounsaville BJ, Nich C, Gordon LT, Wirtz PW, Gawin F: One-year follow-up of psychotherapy and pharmacotherapy for cocaine dependence: delayed emergence of psychotherapy effects. Arch Gen Psychiatry 1994; 51:989-997 (Pubitemid 24371869)
32. Gerasimov MR, Ashby CR Jr, Gardner EL, Mills MJ, Brodie JD, Dewey SL: Gamma-vinyl GABA inhibits methamphetamine, heroin, or ethanol-induced increases in nucleus accumbens dopamine. Synapse 1999; 34:11-19
33. Gillis MC: CPS: Compendium of Pharmaceutical and Specialties. O ttawa, Canadian Pharmaceutical Association, 2002
34. Manuchehri K, Goodman S, Siviter L, Nightingale S: A controlled study of vigabatrin and visual abnormalities. Br J Ophthalmol 2000; 84:499-505 (Pubitemid 30251711)
35. Toggweiler S, Wieser HG: Concentric visual field restriction under vigabatrin therapy: extent depends on the duration of drug intake. Seizure 2001; 10:420-423 (Pubitemid 33114973)
36. Vanhatalo S, Nousiainen I, Eriksson K, Rantala H, Vainionpaa L, Mustonen K, Aarimaa T, Alen R, Aine MR, Byring R, Hirvasniemi A, Nuutila A, Walden T, Ritanen-Mohammed UM, Karttunen-Lewandowski P, Pohjola LM, Kaksonen S, Jurvelin P, Granstrom ML: Visual field constriction in 91 Finnish children treated with vigabatrin. Epilepsia 2002; 43:748-756 (Pubitemid 34774258)
37. Hardus P, Verduin WM, Engelsman M, Edelbroek PM, Segers JP, Berendschot TT, Stilma JS: Visual field loss associated with vigabatrin: quantification and relation to dosage. Epilepsia 2001; 42:262-267 (Pubitemid 32204810)
38. Newman WD, Tocher K, Acheson JF: Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal. Eye 2002; 16:567-571
39. Fechtner RD, Khouri AS, Figueroa E, Ramirez M, Federico M, Dewey SL, Brodie JD: Short-term treatment of cocaine and/or methamphetamine abuse with vigabatrin: ocular safety pilot results. Arch Ophthalmol 2006; 124:1257-1262 (Pubitemid 44379859)